EP1094814A2 - Verfahren sowie zusammensetzungen zur penetrationserhöhung von hiv-proteasehemmer - Google Patents

Verfahren sowie zusammensetzungen zur penetrationserhöhung von hiv-proteasehemmer

Info

Publication number
EP1094814A2
EP1094814A2 EP99927848A EP99927848A EP1094814A2 EP 1094814 A2 EP1094814 A2 EP 1094814A2 EP 99927848 A EP99927848 A EP 99927848A EP 99927848 A EP99927848 A EP 99927848A EP 1094814 A2 EP1094814 A2 EP 1094814A2
Authority
EP
European Patent Office
Prior art keywords
amprenavir
pharmaceutically acceptable
acceptable derivative
hiv
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99927848A
Other languages
English (en)
French (fr)
Inventor
Kenneth Russell Brouwer
Joseph William Polli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1094814A2 publication Critical patent/EP1094814A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP99927848A 1998-06-05 1999-06-03 Verfahren sowie zusammensetzungen zur penetrationserhöhung von hiv-proteasehemmer Withdrawn EP1094814A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9812189 1998-06-05
GBGB9812189.0A GB9812189D0 (en) 1998-06-05 1998-06-05 Methods and compositions for increasing penetration of HIV protease inhibitors
PCT/EP1999/003827 WO1999064001A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Publications (1)

Publication Number Publication Date
EP1094814A2 true EP1094814A2 (de) 2001-05-02

Family

ID=10833305

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99927848A Withdrawn EP1094814A2 (de) 1998-06-05 1999-06-03 Verfahren sowie zusammensetzungen zur penetrationserhöhung von hiv-proteasehemmer

Country Status (5)

Country Link
EP (1) EP1094814A2 (de)
JP (1) JP2002517443A (de)
AU (1) AU4505199A (de)
GB (1) GB9812189D0 (de)
WO (1) WO1999064001A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
JP2000072749A (ja) * 1998-08-24 2000-03-07 Mitsui Chemicals Inc キノリン誘導体を用いるアポトーシス誘導剤
JP2000290181A (ja) * 1999-04-01 2000-10-17 Mitsui Chemicals Inc 脳疾患治療薬脳内移行増強剤
AU2002314914A1 (en) 2001-06-01 2002-12-16 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MXPA03011521A (es) 2001-06-13 2004-03-18 Elan Pharm Inc Aminadioles para tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) 2001-07-10 2004-07-23 Upjohn Co Amindioles para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) 2001-07-10 2004-07-23 Upjohn Co Diamindioles para tratamiento de enfermedad de alzheimer.
BR0213139A (pt) 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
BR0214736A (pt) 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
MXPA05011150A (es) 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
EP1740575A2 (de) 2004-04-22 2007-01-10 Eli Lilly And Company Als bace-inhibitoren geeignete pyrrolidinderivate
EP1773756A2 (de) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oximderivatisubstituierte hydroxyethylaminaspartylproteaseinhibitoren
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2014165087A1 (en) * 2013-03-12 2014-10-09 Hiv Diagnostics, Inc. Mdr method and products for treating hiv/aids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9964001A2 *

Also Published As

Publication number Publication date
AU4505199A (en) 1999-12-30
JP2002517443A (ja) 2002-06-18
GB9812189D0 (en) 1998-08-05
WO1999064001A3 (en) 2000-02-03
WO1999064001A2 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
WO1999064001A2 (en) Methods and compositions for increasing penetration of hiv protease inhibitors
KR100542536B1 (ko) 지도부딘,1592u89및3tc또는ftc의상승작용성복합제제
JP4012070B2 (ja) ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20130029904A1 (en) Hcv combination therapy
JP2003521447A (ja) （３ｓ）テトラヒドロ−３−フラニル（１ｓ，２ｒ）−３−［［（４−アミノフェニル）スルホニル］（イソブチル）アミノ］−１−ベンジル−２−（ホスホノオキシ）プロピルカルバミン酸カルシウム
KR20140082858A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
TW469132B (en) Antiviral combinations
KR20010043128A (ko) 아바카비르, 라미부딘 및 지도부딘을 포함하는 균질 제약조성물
KR100413312B1 (ko) 항바이러스 복합약제
PT1382343E (pt) Terapia de combinação para tratamento do vírus da hepatite b
AU723877C (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
HRP980264A2 (en) Antiviral combinations
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
WO2023286823A1 (ja) 医薬組成物
WO2014148438A1 (ja) ４－（１，１，１，３，３，３－ヘキサフルオロ－２－ヒドロキシプロパン－２－イル）ベンゼン誘導体を含有するｃ型肝炎治療剤
CA2289654A1 (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
KR20010102081A (ko) 치료용 뉴클레오시드 화합물
JP2001509786A (ja) Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、および／または１５９２ｕ８９を含んでなる組合わせ
JPH0544925B2 (de)
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020102